Market Overview:
The global tumor necrosis factor receptor superfamily member 1A market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer and other chronic diseases, rising awareness about available treatment options, and growing investments by pharmaceutical companies in R&D for novel TNF-alpha inhibitors. Based on type, the global tumor necrosis factor receptor superfamily member 1A market is segmented into LY-3232094, EYS-606, SRT-100, and others. LY-3232094 is expected to account for the largest share of this market during the forecast period. This can be attributed to its high efficacy and safety profile compared with other TNF inhibitors currently available in the market. Based on application, this market is segmented into genital warts, melanoma, multiple sclerosis (MS), psoriasis vulgaris (PV), and others.
Product Definition:
The tumor necrosis factor receptor superfamily member 1A (TNFR1) is a protein that in humans is encoded by the TNFRSF1A gene. TNFR1 is a receptor for tumor necrosis factor (TNF), a cytokine that induces apoptosis. The importance of TNFR1 lies in its ability to mediate the cytotoxic effects of TNF on tumors, and it has been proposed as a target for cancer therapy.
LY-3232094:
LY-3232094 is a human interleukin 2 receptor subunit gene. It is also known as TNFRSF1A or IL2R&DEL; it encodes for the Type II cytokine receptor/dimer and has been studied in detail for its role in the regulation of immune responses. LY-3232094 along with other members of the TNFRSF1A family (e.g.
EYS-606:
YS-606 is a selective inhibitor of the JAK1 ( Janus kinase 1) enzyme. It has been reported to have high affinity for JAK1 with a K i of 0.4 nM and excellent selectivity over Tyrosine Kinases including Yes-associated protein (YAP), mammalian target of Rapamycin (mTOR), and farnesyltransferase inhibitors like Roche's RFTI 809035.
Application Insights:
The other application segment includes rheumatoid arthritis, Crohn's disease, osteoarthritis, psoriatic arthritis and others. TNFRSF1A has shown promising results in the treatment of various autoimmune diseases. The presence of a strong pipeline for this drug across different indications is expected to drive the global market over the forecast period.
Genital warts are estimated to be one of the prominent applications for which demand is anticipated to rise at a significant rate during the study period owing to its high success rate in eliminating genital tumors and reducing inflammation associated with them. In addition, increasing awareness about this therapy among patients as well as healthcare professionals is expected fuel growth during this forecast period.
Regional Analysis:
North America dominated the global tumor necrosis factor receptor superfamily member 1A market in 2017. This can be attributed to the presence of a large number of players, high adoption rate for new therapies, and increasing government funding for cancer research. In addition, favorable reimbursement policies in this region are also expected to boost revenue growth over the forecast period. Asia Pacific is expected to witness lucrative growth during the forecast period owing to improving healthcare infrastructure and rising disposable income levels coupled with growing awareness about early diagnosis among consumers. Moreover, an increase in investments by governments & private entities is also anticipated to drive regional market growth over the next eight years (2018-2030).
Growth Factors:
- Increasing incidence of cancer: The incidence of cancer is increasing at an alarming rate across the globe. This is expected to drive the demand for Tumor Necrosis Factor Receptor Superfamily Member 1A (TNFRSF1A) drugs in the coming years.
- Growing awareness about cancer and its treatment options: There is a growing awareness among people about different types of cancers and their treatment options. This is likely to boost the demand for TNFRSF1A drugs in the near future.
- Rising prevalence of lifestyle-related diseases: The prevalence of lifestyle-related diseases such as obesity, diabetes, and heart disease is on the rise globally. This is likely to increase the demand for TNFRSF1A drugs as they are used in the treatment of these diseases.
- Technological advancements in drug development: There has been a significant advancement in technology over recent years that has helped improve drug development process significantly, resulting in better therapies being developed for various indications including cancer therapy market which will fuel growth within tumor necrosis factor receptor superfamily member 1a market . 5 Emerging markets offer significant potential growth opportunities: The emerging markets offer significant potential growth opportunities due to their large population base and rising income levels
Scope Of The Report
Report Attributes
Report Details
Report Title
Tumor Necrosis Factor Receptor Superfamily Member 1A Market Research Report
By Type
LY-3232094, EYS-606, SRT-100, Others
By Application
Genital Warts, Melanoma, Multiple Sclerosis, Psoriasis, Others
By Companies
Addex Therapeutics Ltd, G&E Herbal Biotechnology Co., Ltd., GlaxoSmithKline Plc, Inflamalps SA, Polaris Pharmaceuticals, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Report Segments:
The global Tumor Necrosis Factor Receptor Superfamily Member 1A market is segmented on the basis of:
Types
LY-3232094, EYS-606, SRT-100, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Genital Warts, Melanoma, Multiple Sclerosis, Psoriasis, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Addex Therapeutics Ltd
- G&E Herbal Biotechnology Co., Ltd.
- GlaxoSmithKline Plc
- Inflamalps SA
- Polaris Pharmaceuticals, Inc.
Highlights of The Tumor Necrosis Factor Receptor Superfamily Member 1A Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- LY-3232094
- EYS-606
- SRT-100
- Others
- By Application:
- Genital Warts
- Melanoma
- Multiple Sclerosis
- Psoriasis
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tumor Necrosis Factor Receptor Superfamily Member 1A Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
TNFRSF1A is a protein that belongs to the tumor necrosis factor receptor superfamily. TNFRSF1A is a type I transmembrane protein that functions as an adapter molecule for the binding of ligands, such as TNF-alpha and IL-6, to their respective receptors.
Some of the major companies in the tumor necrosis factor receptor superfamily member 1a market are Addex Therapeutics Ltd, G&E Herbal Biotechnology Co., Ltd., GlaxoSmithKline Plc, Inflamalps SA, Polaris Pharmaceuticals, Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tumor Necrosis Factor Receptor Superfamily Member 1A Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tumor Necrosis Factor Receptor Superfamily Member 1A Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tumor Necrosis Factor Receptor Superfamily Member 1A Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size & Forecast, 2018-2028
4.5.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size and Y-o-Y Growth
4.5.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Market Absolute $ Opportunity
Chapter 5 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Type
5.2.1 LY-3232094
5.2.2 EYS-606
5.2.3 SRT-100
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Applications
6.2.1 Genital Warts
6.2.2 Melanoma
6.2.3 Multiple Sclerosis
6.2.4 Psoriasis
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Analysis and Forecast
9.1 Introduction
9.2 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Type
9.6.1 LY-3232094
9.6.2 EYS-606
9.6.3 SRT-100
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Applications
9.10.1 Genital Warts
9.10.2 Melanoma
9.10.3 Multiple Sclerosis
9.10.4 Psoriasis
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Analysis and Forecast
10.1 Introduction
10.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Type
10.6.1 LY-3232094
10.6.2 EYS-606
10.6.3 SRT-100
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Applications
10.10.1 Genital Warts
10.10.2 Melanoma
10.10.3 Multiple Sclerosis
10.10.4 Psoriasis
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Type
11.6.1 LY-3232094
11.6.2 EYS-606
11.6.3 SRT-100
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Applications
11.10.1 Genital Warts
11.10.2 Melanoma
11.10.3 Multiple Sclerosis
11.10.4 Psoriasis
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Analysis and Forecast
12.1 Introduction
12.2 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Type
12.6.1 LY-3232094
12.6.2 EYS-606
12.6.3 SRT-100
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Applications
12.10.1 Genital Warts
12.10.2 Melanoma
12.10.3 Multiple Sclerosis
12.10.4 Psoriasis
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tumor Necrosis Factor Receptor Superfamily Member 1A Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Type
13.6.1 LY-3232094
13.6.2 EYS-606
13.6.3 SRT-100
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tumor Necrosis Factor Receptor Superfamily Member 1A Market Size Forecast by Applications
13.10.1 Genital Warts
13.10.2 Melanoma
13.10.3 Multiple Sclerosis
13.10.4 Psoriasis
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tumor Necrosis Factor Receptor Superfamily Member 1A Market: Competitive Dashboard
14.2 Global Tumor Necrosis Factor Receptor Superfamily Member 1A Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Addex Therapeutics Ltd
14.3.2 G&E Herbal Biotechnology Co., Ltd.
14.3.3 GlaxoSmithKline Plc
14.3.4 Inflamalps SA
14.3.5 Polaris Pharmaceuticals, Inc.
